Top entities: UroGen Pharma, Levi & Korsinsky, Joseph E. Levi, United States — Food and Drug Administration.

What category does this event fall under?

Business — classified as class action.

What is the sentiment of coverage?

Aggregate sentiment score: -40 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

UroGen Pharma made false statements · Levi & Korsinsky notified investors of lawsuit UroGen Pharma · UroGen Pharma failed to heed warnings United States — Food and Drug Administration

Is this event still developing?

This event is archived — the story has concluded and this page is a final snapshot.

Business class action

UroGen Pharma Class Action Lawsuit

Q: When did this event occur?

First reported Jun 05, 2025; last updated Jun 13, 2025.

Q: What is the market impact?

General. The class action lawsuit against UroGen Pharma could lead to significant financial losses for the company due to legal fees and potential settlements, negatively impacting its stock price.

Analysis based on 7 articles · First reported Jun 05, 2025 · Last updated Jun 13, 2025

Sentiment

-40

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The class action lawsuit against UroGen Pharma could lead to significant financial losses for the company due to legal fees and potential settlements, negatively impacting its stock price. This event also highlights regulatory risks in the pharmaceutical industry, potentially affecting investor confidence in other companies with similar product development challenges.

Pharmaceuticals Legal Services

Event Summary

Levi & Korsinsky has notified investors of a class action securities lawsuit against UroGen Pharma. The lawsuit alleges that UroGen Pharma made false and misleading statements between July 27, 2023, and May 15, 2025, concerning its lead pipeline product, UGN-102. Specifically, the complaint claims that the ENVISION clinical study for UGN-102 lacked a concurrent control arm, making it difficult to prove the drug's effectiveness. Furthermore, UroGen Pharma allegedly ignored warnings from the United States — Food and Drug Administration regarding the study design, creating a substantial risk that the New Drug Application for UGN-102 would not be approved. Investors who suffered losses during this period have until July 28, 2025, to request to be appointed as lead plaintiff.

Key Actions

100 UroGen Pharma made false statements

90 Levi & Korsinsky notified investors of lawsuit UroGen Pharma

85 UroGen Pharma failed to heed warnings United States — Food and Drug Administration

Entities Involved

stock

UroGen Pharma

UroGen Pharma is the defendant in a class action securities lawsuit, facing allegations of making false and misleading statements regarding its lead pipeline product, UGN-102, which could negatively impact its stock price and reputation.

Importance 100.0 Sentiment -50.0

priv

Levi & Korsinsky

Levi & Korsinsky is the law firm notifying investors of the class action lawsuit against UroGen Pharma, seeking to recover losses on behalf of affected shareholders.

Importance 80.0 Sentiment 20.0

per

Joseph E. Levi

Joseph E. Levi is an attorney at Levi & Korsinsky, serving as a contact for investors interested in the class action lawsuit against UroGen Pharma.

Importance 40.0 Sentiment 10.0

govactor

United States — Food and Drug Administration

Importance 0.0 Sentiment 0.0

Relationships

Levi & Korsinsky related ↔ Joseph E. Levi

Levi & Korsinsky related ↔ United States — Food and Drug Administration

Joseph E. Levi related ↔ United States — Food and Drug Administration

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard